Radiopharm Theranostics Advances RAD202 Phase 1 HEAT Trial to Dose Level 3 for HER2+ Solid Tumors

On April 8, 2026, Radiopharm Theranostics announced that its Phase 1 'HEAT' clinical trial for 177Lu-RAD202 (RAD202) has received a positive recommendation from the Data Safety and Monitoring Committee (DSMC) to advance to the third dose level. The trial, which targets patients with HER2-positive advanced solid tumors, will now escalate the dosage to 130mCi following the successful completion of Cohort 2 (75mCi). RAD202 is a proprietary single-domain monoclonal antibody (sdAb) designed to target HER2 expression, a validated oncology target overexpressed in breast and other solid tumors. The company reported that the rapid progression to Cohort 3 underscores the favorable safety profile of the radiotherapeutic asset. Radiopharm remains on track to complete the Phase 1 dose escalation by the end of 2026. The study is currently being conducted across multiple clinical centers in Australia.